Gaia Tabacco1,2, Yu-Kwang Donovan Tay3, Natalie E Cusano4, John Williams1, Beatriz Omeragic1, Rukhana Majeed1, Maximo Gomez Almonte5, Mishaela R Rubin1, John P Bilezikian1. 1. Division of Endocrinology, Department of Medicine, College of Physicians & Surgeons, Columbia University, New York, New York. 2. Unit of Endocrinology and Diabetes, Department of Medicine, University Campus Bio-Medico, Rome, Italy. 3. Department of Medicine, Sengkang General Hospital, Singapore. 4. Division of Endocrinology, Department of Medicine, Lenox Hill Hospital, New York, New York. 5. Division of Cardiology, Department of Medicine, Wyckoff Heights Medical Center, New York, New York.
Abstract
CONTEXT: Calcium and vitamin D treatment does not improve reduced quality of life (QOL) in hypoparathyroidism. Recombinant human (rh) PTH(1-84) therapy improves QOL metrics for up to 5 years. Data on QOL beyond this time point are not available. OBJECTIVES: To evaluate the effects of 8 years of rhPTH(1-84) therapy on QOL and factors associated with long-term benefit. DESIGN: Prospective, open-label trial. SETTING: Referral center. PATIENTS: Twenty patients with hypoparathyoidism. MAIN OUTCOME MEASURES: RAND 36-Item Short Form Health Survey (SF-36). RESULTS: rhPTH therapy led to substantial improvement in five of the eight SF-36 domains [vitality, social functioning (SF), mental health (MH), bodily pain (BP) and general health] and three of these domains (SF, MH, BP) were no longer lower than the reference population. The improvement in the mental component summary (MCS) score was sustained through 8 years, while the physical component summary (PCS) score improved through 6 years. A lower baseline QOL score was associated with greater improvement. A threshold value <238 (MCS) and <245 (PCS) predicted long-term improvement in 90% and 100% of the cohort, respectively. In patients whose calcium supplementation was reduced, MCS and PCS scores improved more than those whose supplementation did not decline to the same extent. Improvement in PCS was greater in patients whose calcitriol dosage was reduced and duration of disease was shorter. CONCLUSIONS: rhPTH(1-84) improves long-term well-being in hypoparathyroidism. The improvements are most prominent in those with impaired SF-36 at baseline and those whose requirements for conventional therapy decreased substantially.
CONTEXT: Calcium and vitamin D treatment does not improve reduced quality of life (QOL) in hypoparathyroidism. Recombinant human (rh) PTH(1-84) therapy improves QOL metrics for up to 5 years. Data on QOL beyond this time point are not available. OBJECTIVES: To evaluate the effects of 8 years of rhPTH(1-84) therapy on QOL and factors associated with long-term benefit. DESIGN: Prospective, open-label trial. SETTING: Referral center. PATIENTS: Twenty patients with hypoparathyoidism. MAIN OUTCOME MEASURES: RAND 36-Item Short Form Health Survey (SF-36). RESULTS: rhPTH therapy led to substantial improvement in five of the eight SF-36 domains [vitality, social functioning (SF), mental health (MH), bodily pain (BP) and general health] and three of these domains (SF, MH, BP) were no longer lower than the reference population. The improvement in the mental component summary (MCS) score was sustained through 8 years, while the physical component summary (PCS) score improved through 6 years. A lower baseline QOL score was associated with greater improvement. A threshold value <238 (MCS) and <245 (PCS) predicted long-term improvement in 90% and 100% of the cohort, respectively. In patients whose calcium supplementation was reduced, MCS and PCS scores improved more than those whose supplementation did not decline to the same extent. Improvement in PCS was greater in patients whose calcitriol dosage was reduced and duration of disease was shorter. CONCLUSIONS: rhPTH(1-84) improves long-term well-being in hypoparathyroidism. The improvements are most prominent in those with impaired SF-36 at baseline and those whose requirements for conventional therapy decreased substantially.
Authors: John P Bilezikian; Aliya Khan; John T Potts; Maria Luisa Brandi; Bart L Clarke; Dolores Shoback; Harald Jüppner; Pierre D'Amour; John Fox; Lars Rejnmark; Leif Mosekilde; Mishaela R Rubin; David Dempster; Rachel Gafni; Michael T Collins; Jim Sliney; James Sanders Journal: J Bone Miner Res Date: 2011-10 Impact factor: 6.741
Authors: Wiebke Arlt; Christian Fremerey; Frank Callies; Martin Reincke; Peter Schneider; Wolfgang Timmermann; Bruno Allolio Journal: Eur J Endocrinol Date: 2002-02 Impact factor: 6.664
Authors: Karen K Winer; Chia Wen Ko; James C Reynolds; Karen Dowdy; Meg Keil; Donna Peterson; Lynn H Gerber; Charles McGarvey; Gordon B Cutler Journal: J Clin Endocrinol Metab Date: 2003-09 Impact factor: 5.958
Authors: Deborah M Mitchell; Susan Regan; Michael R Cooley; Kelly B Lauter; Michael C Vrla; Carolyn B Becker; Sherri-Ann M Burnett-Bowie; Michael Mannstadt Journal: J Clin Endocrinol Metab Date: 2012-10-05 Impact factor: 5.958
Authors: Natalie E Cusano; Mishaela R Rubin; Donald J McMahon; Dinaz Irani; Amanda Tulley; James Sliney; John P Bilezikian Journal: J Clin Endocrinol Metab Date: 2013-04-17 Impact factor: 5.958
Authors: L Mazoni; A Matrone; M Apicella; F Saponaro; S Borsari; E Pardi; B Cosci; I Biagioni; P Rossi; F Pacciardi; A Scionti; R Elisei; C Marcocci; F Cetani Journal: J Endocrinol Invest Date: 2021-10-12 Impact factor: 4.256
Authors: Kelly L Roszko; Tiffany Y Hu; Lori C Guthrie; Beth A Brillante; Michaele Smith; Michael T Collins; Rachel I Gafni Journal: J Bone Miner Res Date: 2021-10-18 Impact factor: 6.390
Authors: Amanda R Doubleday; Sarah E Robbins; Cameron L Macdonald; Dawn M Elfenbein; Nadine P Connor; Rebecca S Sippel Journal: Surgery Date: 2020-07-09 Impact factor: 3.982